Saraf Amanda J, Dickman Paul S, Hingorani Pooja
Nationwide Children's Hospital, Columbus, OH.
Phoenix Children's Hospital, Phoenix, AZ.
J Pediatr Hematol Oncol. 2019 Mar;41(2):118-120. doi: 10.1097/MPH.0000000000001311.
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite aggressive therapy, patients with metastatic or relapsed disease experience dismal outcomes and novel therapies are urgently needed. In this study, we evaluated expression of disialoganglioside (GD2), a cell surface antigen with therapeutic implication, in 16 RMS patient samples. Scoring revealed GD2 positivity in 25% of the samples. These data suggest that a small subset of RMS tumors express GD2, which may be a therapeutic target in these patients.
横纹肌肉瘤（RMS）是最常见的儿童软组织肉瘤。尽管进行了积极治疗，但转移性或复发性疾病患者的预后仍然很差，迫切需要新的治疗方法。在本研究中，我们评估了16例RMS患者样本中双唾液酸神经节苷脂（GD2）的表达，GD2是一种具有治疗意义的细胞表面抗原。评分显示25%的样本中GD2呈阳性。这些数据表明，一小部分RMS肿瘤表达GD2，这可能是这些患者的一个治疗靶点。
